Depressive symptomatology and peripheral neuropathy in type i and type ii diabetics

1984 ◽  
Vol 20 (6) ◽  
pp. 1489
Author(s):  
L. Leedom ◽  
A. Zeidler ◽  
R. McIntyre ◽  
J. Hoffman ◽  
D. Baron ◽  
...  
BMJ ◽  
1986 ◽  
Vol 292 (6536) ◽  
pp. 1671-1671 ◽  
Author(s):  
B G Jacob ◽  
W O Richter ◽  
P Schwandt ◽  
A Fateh-Moghadam ◽  
T N Witt

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Kurai Z. Chako ◽  
Heather Phillipo ◽  
Erisi Mafuratidze ◽  
Danai Tavonga Zhou

Diabetics have chronically elevated glucose levels. High levels of glucose result in nonenzymatic formation of glycosylated haemoglobin (HbA1c). Therefore, elevated HbA1c is a good indicator of poorly controlled diabetes. We used the standard HbA1c method to determine glycemic control in diabetics attending a public health facility in Harare, Zimbabwe. Our study sought to assess the prevalence of elevated HbA1c amongst treated diabetics and compare the HbA1c levels by type of diabetes. The cross-sectional study was carried out at one of the main public health centres in Zimbabwe: the Parirenyatwa Group of Hospitals in Harare. Type I and type II diabetics were recruited and had their blood HbA1c levels measured. The standard one tailed proportion z test was used to test the hypothesis at 5% significance level. Combined prevalence of type I and type II diabetics with elevated HbA1c was 27%. There was no significant difference in levels of HbA1c by age and sex. Over half (54%) of Type I diabetics had elevated HbA1c, suggesting poor glycemic control. In contrast only 24% of the Type II diabetics studied had elevated HbA1c. The difference in proportion of Type I and Type II diabetics with elevated HbA1c suggestive of poor glycemic control was significant (P=0.0067).


1997 ◽  
Vol 176 (1) ◽  
pp. S177
Author(s):  
DA Sacks ◽  
JS Greenspoon ◽  
G Wolde-Tsadik ◽  
W. Chen

1984 ◽  
Vol 20 (6) ◽  
pp. 1489
Author(s):  
M.J. MacDonald ◽  
O.O. Famuyiwa ◽  
M. Marrari ◽  
R.J. Duquesnoy

1987 ◽  
Vol 24 (3) ◽  
pp. 181-192 ◽  
Author(s):  
Sotos Raptis ◽  
Asimina Mitrakou ◽  
Dimitrios Hadjidakis ◽  
Emmanuel Diamantopoulos ◽  
Costas Anastasiou ◽  
...  

1985 ◽  
Vol 22 (3) ◽  
pp. 185-190 ◽  
Author(s):  
Wim F. Vanroelen ◽  
Luc F. Gaal ◽  
Patricia E. Rooy ◽  
Ivo H. Leeuw
Keyword(s):  
Type I ◽  
Type Ii ◽  

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 408
Author(s):  
Martin G. Rosario ◽  
Elizabeth Orozco ◽  
Nairoby Babilonia ◽  
Greisy Tellez ◽  
Francheska Mojica ◽  
...  

Background: Patients with diabetes have been shown to suffer from increased fall risk. Research shows that this risk is higher on irregular surfaces. Existing studies evaluate gait on irregular surfaces, such as stairs, asphalt, grass and stones. This study evaluates gait parameters in individuals with diabetes mellitus type II (DMII) with no history of peripheral neuropathy, while ascending and descending a ramp at an imposed speed, and compares them with healthy controls. Methods: Fifteen healthy volunteer participants and fifteen participants with DMII and no peripheral neuropathy (females and males) between the ages of 40-65 were recruited for this study. Participants walked three times at 100 bpm while ascending and descending a wooden ramp. Temporospatial and kinematic parameters were analyzed. Results: We observed minimal changes in temporospatial and kinetic parameters in people with controlled DMII with no evidence of peripheral neuropathy.  Conclusion: Focusing on individuals with controlled DMII allowed us to determine if only the diagnosis of diabetes without peripheral neuropathy influenced gait parameters. Clinicians and researchers should focus their assessments on neuromuscular activation during this stage of the condition, thus preventing complications, such as abnormal gait, that increases the risk for falls.


2021 ◽  
Vol 12 ◽  
Author(s):  
Scott J. Howell ◽  
Chieh A. Lee ◽  
Julia C. Batoki ◽  
Thomas E. Zapadka ◽  
Sarah I. Lindstrom ◽  
...  

The global number of diabetics continues to rise annually. As diabetes progresses, almost all of Type I and more than half of Type II diabetics develop diabetic retinopathy. Diabetic retinopathy is a microvascular disease of the retina, and is the leading cause of blindness in the working-age population worldwide. With such a significant health impact, new drugs are required to halt the blinding threat posed by this visual disorder. The cause of diabetic retinopathy is multifactorial, and an optimal therapeutic would halt inflammation, cease photoreceptor cell dysfunction, and ablate vascular impairment. XMD8-92 is a small molecule inhibitor that blocks inflammatory activity downstream of ERK5 (extracellular signal-related kinase 5) and BRD4 (bromodomain 4). ERK5 elicits inflammation, is increased in Type II diabetics, and plays a pathologic role in diabetic nephropathy, while BRD4 induces retinal inflammation and plays a role in retinal degeneration. Further, we provide evidence that suggests both pERK5 and BRD4 expression are increased in the retinas of our STZ (streptozotocin)-induced diabetic mice. Taken together, we hypothesized that XMD8-92 would be a good therapeutic candidate for diabetic retinopathy, and tested XMD8-92 in a murine model of diabetic retinopathy. In the current study, we developed an in vivo treatment regimen by administering one 100 μL subcutaneous injection of saline containing 20 μM of XMD8-92 weekly, to STZ-induced diabetic mice. XMD8-92 treatments significantly decreased diabetes-mediated retinal inflammation, VEGF production, and oxidative stress. Further, XMD8-92 halted the degradation of ZO-1 (zonula occludens-1), which is a tight junction protein associated with vascular permeability in the retina. Finally, XMD8-92 treatment ablated diabetes-mediated vascular leakage and capillary degeneration, which are the clinical hallmarks of non-proliferative diabetic retinopathy. Taken together, this study provides strong evidence that XMD8-92 could be a potentially novel therapeutic for diabetic retinopathy.


2009 ◽  
Vol 104 (06) ◽  
pp. 420-430 ◽  
Author(s):  
E. Haupt ◽  
R. Herrmann ◽  
A. Benecke-Timp ◽  
H. Vogel ◽  
J. Hilgenfeldt ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document